Elmer Murdock, MD
Interventional Cardiology · Elmhurst, ILNPI 1700064730
Payments from drug & device makers
Across 543 payments — averaging $229.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$91K
- Lilly USA, LLC$24K
- Teleflex LLC$2K
- Boston Scientific$1K
- Amgen$1K
- Novartis$795
- plus $4K from 33 others
What the payments were for
- Consulting fees$4,1003%
- Speaking & faculty fees$103,56983%
- Travel & lodging$4,0683%
- Food & beverage$13,05010%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 151 | $91,435 |
| Lilly USA, LLC | 24 | $24,219 |
| Teleflex LLC | 14 | $1,678 |
| Boston Scientific | 24 | $1,140 |
| Amgen | 60 | $1,065 |
| Novartis | 39 | $795 |
| Pfizer | 37 | $710 |
| Johnson & Johnson | 37 | $571 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $507 |
| Novo Nordisk | 11 | $347 |
| E.r. Squibb & Sons, L.L.C. | 23 | $312 |
| Abbott | 10 | $263 |
| AstraZeneca | 13 | $197 |
| Sanofi-aventis U.S. LLC | 9 | $162 |
| Chiesi USA, Inc. | 9 | $153 |
| Regeneron Healthcare Solutions, Inc. | 7 | $150 |
| Philips North America LLC | 3 | $142 |
| Acist Medical Systems, Inc. | 3 | $127 |
| Inari Medical, Inc. | 3 | $92 |
| Imperative Care, Inc | 3 | $68 |
| Heartflow, Inc. | 3 | $68 |
| Scpharmaceuticals Inc. | 3 | $62 |
| Bard Peripheral Vascular, Inc. | 4 | $59 |
| Merck | 3 | $53 |
| Elutia, Inc. | 4 | $45 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Bridgebio Pharma, Inc. | 2 | $38 |
| Medtronic | 2 | $36 |
| Surmodics, Inc. | 3 | $33 |
| Shockwave Medical, Inc | 2 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $31 |
| Cvrx, Inc. | 1 | $29 |
| Cordis US CORP. | 1 | $28 |
| Edwards Lifesciences | 1 | $23 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Angiodynamics, Inc. | 1 | $23 |
| Veryan Medical Incorporated | 1 | $17 |
| Abiomed | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$112,262
- GUIDELINER$1,471
- GENERAL VASCULAR ACCESS$281
- VASCULAR$263
- Ozempic$131
- (6585) Omniwire$116
- WATCHMAN Access System$110
How this compares
$124,809 in reported general payments places this provider in the 85th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 218 | $229,370 |
| JardianceEmpagliflozin | 127 | $147,054 |
| XareltoRivaroxaban | 78 | $83,673 |
| Repatha SureclickEvolocumab | 70 | $73,317 |
| EntrestoSacubitril/Valsartan | 60 | $61,278 |
| MultaqDronedarone Hcl | 21 | $30,918 |
| BrilintaTicagrelor | 19 | $16,282 |
| Praluent PenAlirocumab | 22 | $11,837 |
| Metoprolol Succinate | 431 | $5,776 |
| ClopidogrelClopidogrel Bisulfate | 405 | $4,409 |
| Rosuvastatin Calcium | 342 | $4,406 |
| Atorvastatin Calcium | 459 | $4,038 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 75 | $2,345 |
| Ezetimibe | 74 | $1,942 |
| Amlodipine Besylate | 290 | $1,779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $710 | $229,370218 claims |
| Boehringer IngelheimJardiance | $91,435 | $147,054127 claims |
| Johnson & JohnsonXarelto | $571 | $83,67378 claims |
| NovartisEntresto | $795 | $61,27860 claims |
| Sanofi-aventis U.S. LLCMultaq | $162 | $30,91821 claims |
| AstraZenecaBrilinta | $197 | $16,28219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Elmhurst
- Charles DavidsonChicago$5.8M
- Ravi RamanaPalos Park$2.8M
- Mark RicciardiEvanston$2.2M
- Andrei PopElk Grove Village$1.9M
- Krishna Rocha SinghSpringfield$1.7M
- Bruce LewisMaywood$1.3M
- Justin LevisayEvanston$837K
- Atman ShahChicago$794K
- Laura DavidsonChicago$661K
- Sunil AgarwalSpringfield$609K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.